Navigation Links
Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
Date:5/20/2008

Analysis Reveals Overall Survival Could be Extended if Patients Receive the

Most Effective Treatment Identified by ChemoFx

CHICAGO, May 20 /PRNewswire/ -- Precision Therapeutics Inc. announced today that the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlates with significantly longer overall survival (OS) in patients with primary ovarian cancer. Patients who received a treatment determined by ChemoFx to lead to the best tumor response had an overall survival 1.4 times longer than those receiving a treatment shown by ChemoFx to be non-responsive.

Despite the fact that all patients had the same type of tumor, 88 percent of patients exhibited varying degrees of response to different agents when evaluated by the cell-based test. The analysis also found that nearly two-thirds of patients' tumors were more responsive to a treatment identified by ChemoFx, than to the treatment they actually received. Based on these results, a mathematical model was created to estimate survival had patients been treated with a drug that ChemoFx identified as more likely to result in a greater tumor response. The analysis found that median OS could be extended as much as 23 to 38 months.

"These overall survival data demonstrate that the responsiveness to treatment established by this sensitivity assay in the laboratory setting, may in fact translate into meaningful clinical outcomes for patients," said Thomas J. Herzog, MD, director of gynecologic oncology at the Columbia University Medical Center and lead investigator of the study. "If these results are confirmed in current ongoing trials, this will be a significant step towards establishing individualized treatment strategies for patients who will require chemotherapy."

About the Study

Patients analyzed in the study had stage II-IV primary epithelial ovarian cancer that was tested by ChemoFx between 1997 an
'/>"/>

SOURCE Precision Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014  Express Scripts (NASDAQ: ... 2015 Express Scripts Medicare ® Prescription Drug Plans ... Walgreens (NYSE: WAG ) (NASDAQ: ... and clinical support  for their Medicare dollars. ... Value or Choice plans for ...
(Date:10/1/2014)... 1, 2014 Ardelyx, Inc. (NASDAQ: ... company focused on cardio-renal, gastrointestinal and metabolic ... 371 patient Phase 2b clinical trial evaluating ... syndrome (IBS-C).  Results from this study demonstrated ... IBS-C symptoms for tenapanor-treated patients compared to ...
(Date:9/30/2014)... , Sept. 30, 2014 /CNW/ - Protecting the health and safety ... Health Canada uses the appropriate powers and tools at its disposal ... safety and quality standards. To that end, Health ... stop the import into Canada of all ... . They are: , Apotex Pharmachem India Pvt ...
Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2
... Pacific Bridge Medical will be attending the Medical ... 28-30, 2010, at the Donald E. Stephens Convention ... is part of a national conference series for ... affairs within the pharmaceutical and medical device manufacturing ...
... 23 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... M. Bate to its Board of Directors. "We ... to our Board of Directors.  With experience, vision and proven ... to take on this important role in the company," said ...
Cached Medicine Technology:Asian Medical Markets Expert to Attend the MD&M Midwest Conference 2BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors 2BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors 3
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 Bedros ... Fit Body Boot Camp fitness boot camps, he’s also ... personal training , with sold out business summits, a ... as marketing consultant to a recent Spike TV reality ... says that now is the time for personal trainers ...
(Date:10/1/2014)... Hillsboro, Oregon (PRWEB) October 01, 2014 ... curing solutions , continues to expand the business worldwide. ... engineering along with additional capacity for manufacturing efforts. The ... over the last five years and expects this growth ... UV LED curing technology gains worldwide adoption. , ...
(Date:10/1/2014)... MO (PRWEB) October 01, 2014 Join the ... Castlewood Eating Disorder Treatment Center’s first ever charity golf tournament ... for people with eating disorders who cannot afford treatment. The ... Golf Club in Eureka, Mo. , The day-long event ... noon. A reception and award dinner will begin at 5 ...
(Date:10/1/2014)... October 01, 2014 Between 23 million ... the U.S., according to figures from the National Institutes ... Association (AARDA), and many of them have something else ... having undiagnosed celiac disease. Gluten Free Therapeutics, makers ... of undiagnosed celiac disease by publishing a series of ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... Financial contracts to care for sick or aging relatives ... new interest as everyday Americans wrestle with the time and ... legal expert says. , Law professor Richard L. Kaplan says ... a groundswell, and most people still bristle at the notion ...
... 27 Warner Chilcott Limited (Nasdaq: WCRX ) ... has filed for standard review the new drug application (NDA) ... NDA for WC 3016 was submitted by its subsidiary, Warner ... Warner Chilcott , Warner Chilcott is a leading ...
... Today, the Children,s Health Fund (CHF) announced a ... support a new health care clinic in the South ... Starr International Foundation grant will support the clinic,s medical ... The homeless health care clinic is part of the ...
... Inc. (OTC Bulletin Board: NVLX), an emerging healthcare ... distribute Infinitink (the world,s first permanent tattoo ink ... Zealand. The distribution agreement grants Jayhur Enterprises (Sydney, ... market, distribute and sell ...
... Kandahar, Afghanistan could help surgeons prepare for civilian disasters, ... two tours at the hospital. Dr. Vivian McAlister ... the Schulich School of Medicine & Dentistry at The ... the London Health Sciences Centre. He spent two months ...
... can lead to healthier livesST. LOUIS, May 27 ... rollout a new consumer health tool that will complement ... customers. Nurse Response will offer the Healthwise Knowledgebase, an ... Response consumers to access over 7,000 health topics online. ...
Cached Medicine News:Health News:Contracts adding legal twist to family health care 2Health News:Contracts adding legal twist to family health care 3Health News:Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive 2Health News:Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive 3Health News:Children's Health Fund Receives $500,000 from the Starr International Foundation to Support South Bronx Homeless Health Care Clinic 2Health News:Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the World's First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand 2Health News:Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the World's First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand 3Health News:Sharing surgical lessons from the Canadian field hospital in Afghanistan 2
... Our popular Back-Aid Apron ... improved Universal Back-Saver Belt that ... take more weight off your ... shoulder strap redistribute weight from ...
Freedom of movement - plus full circle, maximum radiation protection. No other full circle radiation protection design approaches the level of comfort of the VestSkirt, which divides weight between t...
... Cryo System is the first in portability and performance. ... surgeons who need a flexible, portable system with the ... CTU attaches easily to an "E" size tank and ... cryo to where it is needed.,The CTU Travel Case ...
... System is an easy-to-use, workflow-based system designed to ... Inspirex consists of the SleepWorks software and either ... and durable systems can be used for a ... - including full EEG recording - and have ...
Medicine Products: